Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) saw an uptick in trading volume on Friday . 37,997 shares traded hands during trading, an increase of 136% from the previous session's volume of 16,124 shares.The stock last traded at $11.64 and had previously closed at $12.31.
Analyst Ratings Changes
Several research analysts have issued reports on NBTX shares. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a report on Friday. Leerink Partners set a $14.00 price target on Nanobiotix in a report on Thursday. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.00.
Read Our Latest Report on NBTX
Nanobiotix Trading Down 6.0%
The stock has a 50-day moving average of $7.97 and a 200 day moving average of $5.32.
Institutional Trading of Nanobiotix
A hedge fund recently bought a new stake in Nanobiotix stock. Jane Street Group LLC bought a new position in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 23,283 shares of the company's stock, valued at approximately $73,000. 38.81% of the stock is owned by hedge funds and other institutional investors.
About Nanobiotix
(
Get Free Report)
Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.
Further Reading
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
